



## **Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)**

July 10, 2026 at 7:01 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Jul. 10, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS<sup>®</sup> platform to develop *in vivo* gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards consist of an aggregate total of 114,622 restricted stock units ("RSUs"), granted among three employees in connection with their commencement of employment. Each award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.

The employees' RSUs vest (subject to continued service to Precision through the applicable vesting dates) in substantially equal annual installments on each of the first three anniversaries of the date of the commencement of their employment.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>®</sup> genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of clinical stage *in vivo* gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

The ARCUS<sup>®</sup> platform is being used to develop *in vivo* gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company's PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company's PBGENE-DMD program) and gene insertion (inserting DNA into gene to cause expression/add function).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260710568496/en/>

### **Investor and Media Contact:**

Naresh Tanna

Vice President, Investor Relations

[Naresh.Tanna@precisionbiosciences.com](mailto:Naresh.Tanna@precisionbiosciences.com)

Source: Precision BioSciences, Inc.